Why Is OGN Stock Rising In Pre-Market Today?

• Sun Pharma is reportedly competing against Swedish private equity firm EQT and German pharmaceutical company Grünenthal to acquire the company.
• Organon is considered a valuable target due to its strong footprint in women’s health, spanning breast cancer, contraception, osteoporosis, and menopause.
• Earlier this month, the Economic Times reported that Sun Pharmaceutical is set to proceed with a $12 billion offer to buy Organon.

Organon & Co. (OGN) sparked fresh investor optimism after the stock jumped more than 9% in pre-market trading on Friday, after a report said India’s Sun Pharmaceutical Industries submitted a binding $13 billion offer to acquire the debt-laden drugmaker.

According to an Economic Times report on Friday, Sun Pharma, India’s largest drugmaker by market value, is locked in a competitive bidding war for Organon, facing off against Swedish private equity firm EQT and German pharmaceutical company Grünenthal.

The update comes two weeks after the Economic Times reported that Sun Pharmaceutical is set to proceed with a $12 billion offer to buy out Organon.

Why Sun Pharma Wants Organon

Organon is considered a valuable target due to its strong footprint in women’s health, spanning breast cancer, contraception, osteoporosis, and menopause, as well as its expanding biosimilars portfolio. The firm was spun off from Merck & Co. in June 2021.

“Organon's longer-term positioning remains strong, as women's health growth rebounds and biosimilars become a more meaningful growth driver with recent portfolio expansion. The company also has a solid asset in VTAMA (skin medicine),” Navann Ty of BNP Paribas told the Economic Times.

Organon carried debt of $8.64 billion as of Dec. 31, 2025, while its cash and cash equivalents stood at $574 million. The company is reportedly working with Morgan Stanley to explore a sale of parts of its business or the entire company.

How Did Retail Traders React?

Despite the sharp pre-market gains, retail sentiment on for OGN on Stocktwits remained in the ‘bearish’ territory over the past 24 hours.

One user speculated that the reported buyout offer would result in a consideration of $18 per share. OGN shares closed at $8.6 on Thursday.

The stock has gained more than 20% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.